Tryotex: Hi there I have recently received... - Thyroid UK

Thyroid UK

139,475 members • 163,716 posts

Tryotex

9 years ago•2 Replies

Hi there I have recently received Tryotex 75mcgs capsules and I wonder if anyone can tell me if these are slow release caps as some sites say it is and others not. Can you help? I normally take 75mcgs in 3 doses daily. Thanks

Written by

s24annmarie

To view profiles and participate in discussions please or .

The ability to reply to this post has been turned off.

2 Replies

•

Clutter9 years ago

S24annmarie, there's so much confusion about Triyotex 75mcg I wonder whether it was once slow release but is now regular. If there is no statement that it is either slow or timed release I suspect it is regular release.

I've used Google to translate product details and there is no mention of slow or timed release.

"INDICATIONS: CYTOMEL * is indicated for the treatment of hypothyroidism.

Thyroid hormone has anabolic action promotes protein synthesis and increases metabolism. Has 4 times higher pharmacological potency than levothyroxine (T4).

After oral administration of CYNOMEL *, about 95% absorbed in the gastrointestinal tract and easily reaches the tissues. Intestinal absorption is better than levothyroxine.

The maximum activity of the sodium liothyronine is fast and occurs a few hours after being ingested. The maximum pharmacological response occurs within the first 3 days and provides almost immediate clinical response.

Its biological half-life is approximately 1-2 days and the effect lasts for more than 72 hours after stopping administration. The action of the drug is stopped quickly, allowing immediate dosage adjustments and facilitates the control of an overdose, if it were to occur.

PRECAUTIONS: CYNOMEL * should be administered with caution in patients with cardiovascular disease, including high blood pressure. Any cardiovascular complication required a reduction in dose.

In patients in whom hypothyroidism is secondary to hypopituitarism, it is likely to coexist adrenal insufficiency.

When this happens, the latter must be corrected by corticosteroid prior to administration of thyroid hormones.

Use in Pregnancy and Lactation: Thyroid hormones do not readily cross the placental barrier. Clinical experience suggests that CYNOMEL * no adverse effects on the fetus when administered during pregnancy. Based on this knowledge, thyroid replacement therapy to hypothyroid women should not be discontinued during pregnancy.

Thyroid hormones are excreted in small quantities in breast milk and its use has not been associated with serious adverse reactions; however, caution should be exercised when thyroid hormones are administered to women during lactation.

ADVERSE REACTIONS: Excessive doses of thyroid hormones can lead to signs and symptoms of hyperthyroidism: excitability, weight loss, palpitations, arrhythmia, tachycardia, diarrhea, sweating, tremor, headache and heat intolerance. The effects do not occur immediately and symptoms can appear 1-2 weeks after the initial dose.

In these cases medication should be stopped until the symptoms disappear, to restart one or two days later at lower doses.

Thyroid hormones may enhance the toxic effects of digitalis; Also, thyroid replacement therapy increases the metabolic rate, which may require an increase in the dose of digitalis. It has been reported that concomitant administration of thyroid hormones and ketamine can cause hypertension and tachycardia. Thyroid hormones increase the adrenergic effect of catecholamines such as epinephrine and norepinephrine.

PRECAUTIONS IN RELATION TO EFFECTS OF Carcinogenesis, Mutagenesis, Impairment of Fertility: No studies have been conducted in animals over time to evaluate carcinogenic potential, mutagenic, teratogenic or effects on fertility.

DOSAGE AND ADMINISTRATION: Oral.

CYNOMEL * is generally administered in a single dose, preferably before breakfast.

In moderate hypothyroidism and reproductive disorders caused by hypothyroidism, the recommended starting dose is one tablet daily. The dosage should be adjusted according to the response, with gradual increases in average daily tablet every 1-2 weeks. The usual maintenance dose is one to three tablets daily.

REPRESENTATIONS AND MANAGEMENT Overdosage: In case of overdose, there may be symptoms such as headache, irritability, nervousness, excessive sweating, tachycardia, increased intestinal motility. You can exacerbate cases of angina pectoris or congestive heart failure and shock may develop box.

Excessive dosage may have symptoms that suggested a thyroid crisis, and produce manifestations of hyperthyroidism. In any of these cases, treatment should be suspended for several days and start it again, but with a lower dose. If overdose is severe, drug absorption with the induction of vomiting and gastric lavage should be avoided. Treatment in cases of shock is supportive measures and treatment should be considered for unrecognized adrenal insufficiency. To address the increased sympathetic activity may include adrenergic drugs such as propranolol."

___________________________________________________________________________________

I am not a medical professional and this information is not intended to be a substitute for medical guidance from your own doctor. Please check with your personal physician before applying any of these suggestions.

helvellaAdministratorThyroid UK in reply to Clutter9 years ago

I agree, Clutter, that at one time there was some information which said it was slow release. More recently it has been stated categorically by several people that it is standard release. When I searched (very hard) to find what had made me think it slow release, I could not find anything, anywhere.